Literature DB >> 28233639

MYC: Master Regulator of Immune Privilege.

Stephanie C Casey1, Virginie Baylot1, Dean W Felsher2.   

Abstract

Cancers are often initiated by genetic events that activate proto-oncogenes or inactivate tumor-suppressor genes. These events are also crucial for sustained tumor cell proliferation and survival, a phenomenon described as oncogene addiction. In addition to this cell-intrinsic role, recent evidence indicates that oncogenes also directly regulate immune responses, leading to immunosuppression. Expression of many oncogenes or loss of tumor suppressors induces the expression of immune checkpoints that regulate the immune response, such as PD-L1. We discuss here how oncogenes, and in particular MYC, suppress immune surveillance, and how oncogene-targeted therapies may restore the immune response against tumors.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28233639      PMCID: PMC5378645          DOI: 10.1016/j.it.2017.01.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  74 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

Review 3.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 4.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

5.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

6.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

7.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

8.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

Authors:  Hengrui Zhu; Fee Bengsch; Nikolaos Svoronos; Melanie R Rutkowski; Benjamin G Bitler; Michael J Allegrezza; Yuhki Yokoyama; Andrew V Kossenkov; James E Bradner; Jose R Conejo-Garcia; Rugang Zhang
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

Review 9.  Integrated control of cell proliferation and cell death by the c-myc oncogene.

Authors:  G Evan; E Harrington; A Fanidi; H Land; B Amati; M Bennett
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1994-08-30       Impact factor: 6.237

10.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.

Authors:  Chie Kudo-Saito; Hiromi Shirako; Tadashi Takeuchi; Yutaka Kawakami
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  33 in total

Review 1.  Polyamine synthesis as a target of MYC oncogenes.

Authors:  André S Bachmann; Dirk Geerts
Journal:  J Biol Chem       Date:  2018-11-07       Impact factor: 5.157

Review 2.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

Review 3.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 4.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

5.  Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.

Authors:  Sabine Heitzeneder; Elena Sotillo; Jack F Shern; Sivasish Sindiri; Peng Xu; Robert Jones; Michael Pollak; Pernille R Noer; Julie Lorette; Ladan Fazli; Anya Alag; Paul Meltzer; Ching Lau; Cheryl A Conover; Claus Oxvig; Poul H Sorensen; John M Maris; Javed Khan; Crystal L Mackall
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

6.  Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC.

Authors:  Isabel A English; Rosalie C Sears
Journal:  Cancer Discov       Date:  2020-04       Impact factor: 39.397

7.  MYC gene associated polymorphisms and Wilms tumor risk in Chinese children: a four-center case-control study.

Authors:  Jiabin Liu; Rui-Xi Hua; Wen Fu; Jinhong Zhu; Wei Jia; Jiao Zhang; Haixia Zhou; Jiwen Cheng; Huimin Xia; Guochang Liu; Jing He
Journal:  Ann Transl Med       Date:  2019-09

8.  Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.

Authors:  Elizabeth A Bowling; Jarey H Wang; Fade Gong; William Wu; Nicholas J Neill; Ik Sun Kim; Siddhartha Tyagi; Mayra Orellana; Sarah J Kurley; Rocio Dominguez-Vidaña; Hsiang-Ching Chung; Tiffany Y-T Hsu; Julien Dubrulle; Alexander B Saltzman; Heyuan Li; Jitendra K Meena; Gino M Canlas; Srinivas Chamakuri; Swarnima Singh; Lukas M Simon; Calla M Olson; Lacey E Dobrolecki; Michael T Lewis; Bing Zhang; Ido Golding; Jeffrey M Rosen; Damian W Young; Anna Malovannaya; Fabio Stossi; George Miles; Matthew J Ellis; Lihua Yu; Silvia Buonamici; Charles Y Lin; Kristen L Karlin; Xiang H-F Zhang; Thomas F Westbrook
Journal:  Cell       Date:  2021-01-14       Impact factor: 41.582

9.  Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns.

Authors:  Zhenli Li; Geng Chen; Zhixiong Cai; Xiuqing Dong; Lei He; Liman Qiu; Yongyi Zeng; Xiaolong Liu; Jingfeng Liu
Journal:  Chin J Cancer Res       Date:  2021-06-30       Impact factor: 5.087

10.  Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.

Authors:  Lei Zhu; Zhen Chen; Hongjing Zang; Songqing Fan; Jiajia Gu; Guojing Zhang; Kevin D-Y Sun; Qiming Wang; Yong He; Taofeek K Owonikoko; Suresh S Ramalingam; Shi-Yong Sun
Journal:  Cancer Res       Date:  2021-07-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.